Evidence map›Paper›PMID 39289635›Full record

ArticleBMC public health2024

Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing.

Amy E Leader, Timothy R Rebbeck, William K Oh, Alpa V Patel, Eric P Winer, LeeAnn O Bailey, Leonard G Gomella, Crystal Y Lumpkins, Isla P Garraway, Lisa B Aiello and 25 more

Abstract read
In one paragraph

Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Amy E LeaderDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Timothy R RebbeckDepartment of Epidemiology, Harvard TH Chan School of Public Health and Dana-Farber Cancer Institute, Boston, MA, USA.
William K OhDepartment of Internal Medicine, Mount Sinai Hospital, New York, NY, USA.
Alpa V PatelDepartment of Population Science, American Cancer Society, Atlanta, GA, USA.
Eric P WinerDepartment of Medicine, Yale Cancer Center and Yale School of Medicine, 333 Cedar Street, WWW214A, New Haven, CT, 06520, USA.
LeeAnn O BaileyNational Cancer Institute/Center to Reduce Cancer Health Disparities, Rockville, MD, USA.
Leonard G GomellaDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Crystal Y LumpkinsDepartment of Communication, Population Sciences Division, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Isla P GarrawayDepartment of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Lisa B AielloCorporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA.
Monica L BaskinDepartment of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Heather H ChengDepartment of Medicine, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA.
Kathleen A CooneyDepartment of Medicine, Duke University School of Medicine and Duke Cancer Institute, Durham, NC, USA.
Amanda GanzakCancer Genetics and Prevention Program, Yale New Haven Hospital, New Haven, CT, USA.
Daniel J GeorgeDepartment of Medicine, Duke University School of Medicine and Duke Cancer Institute, Durham, NC, USA.
Susan HalabiDepartment of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, NC, USA.
Feighanne HathawayDepartment of Medicine, High-Risk and Advanced Prostate Cancer Clinic, University of Chicago Medicine, University of Chicago, Chicago, IL, USA.
Claire HealyCancer Genetics and Prevention Program, Yale New Haven Hospital, New Haven, CT, USA.
Joseph W KimDepartment of Medicine, Yale Cancer Center and Yale School of Medicine, 333 Cedar Street, WWW214A, New Haven, CT, 06520, USA.
Michael S LeapmanDepartment of Urology, Yale School of Medicine, New Haven, CT, USA.
Stacy LoebDepartment of Urology and Population Health, New York University and Manhattan Veterans Affairs, New York, NY, USA.
Kara N MaxwellDepartment of Medicine-Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Christopher McNairDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Todd M MorganDepartment of Urology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Breanne PrindevilleNeaman Center for Personalized Medicine, NorthShore University Health System, Evanston, IL, USA.
Howard R SouleProstate Cancer Foundation, Santa Monica, CA, USA.
Whitney L StewardNational Cancer Institute/Center to Reduce Cancer Health Disparities, Rockville, MD, USA.
Sakinah C SuttiratanaDepartment of Medicine, Yale Cancer Center and Yale School of Medicine, 333 Cedar Street, WWW214A, New Haven, CT, 06520, USA.
Mary-Ellen TaplinDepartment of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.
Kosj YamoahDepartmetnt of Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Thierry FortuneDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Kris BennettMovember, Santa Monica, CA, USA.
Joshua Blanding-GodboltDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Laura GrossDepartment of Medicine, Yale University and Yale Cancer Center, New Haven, CT, USA.
Veda N GiriDepartment of Medicine, Yale Cancer Center and Yale School of Medicine, 333 Cedar Street, WWW214A, New Haven, CT, 06520, USA. Veda.Giri@yale.edu.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

backgroundBlack men consistently have higher rates of prostate cancer (PCA)- related mortality. Advances in PCA treatment, screening, and hereditary cancer assessment center around germline testing (GT). Of concern is the significant under-engagement of Black males in PCA GT, limiting the benefit of precision therapy and tailored cancer screening despite longstanding awareness of these disparities. To address these critical disparities, the Socioecological Model (SEM) was employed to develop comprehensive recommendations to overcome barriers and implement equitable strategies to engage Black males in PCA GT.

methodsClinical/research experts, national organization leaders, and community stakeholders spanning multiple regions in US and Africa participated in developing a framework for equity in PCA GT grounded in the SEM. A novel mixed-methods approach was employed to generate key areas to be addressed and informed statements for consensus consideration utilizing the modified Delphi model. Statements achieving strong consensus (> =75% agreement) were included in final equity frameworks addressing clinical/community engagement and research engagement.

resultsAll societal levels of the SEM (interpersonal, institutional, community, and policy/advocacy) must deliver information about PCA GT to Black males that address benefits/limitations, clinical impact, hereditary cancer implications, with acknowledgment of mistrust (mean scores [MS] 4.57-5.00). Interpersonal strategies for information delivery included engagement of family/friends/peers/Black role models to improve education/awareness and overcome mistrust (MS 4.65-5.00). Institutional strategies included diversifying clinical, research, and educational programs and integrating community liaisons into healthcare institutions (MS 4.57-5.00). Community strategies included partnerships with healthcare institutions and visibility of healthcare providers/researchers at community events (MS 4.65-4.91). Policy/advocacy included improving partnerships between advocacy and healthcare/community organizations while protecting patient benefits (MS 4.57-5.00). Media strategies were endorsed for the first time at every level (MS 4.56-5.00).

conclusionThe SEM-based equity frameworks proposed provide the first multidisciplinary strategies dedicated to increase engagement of Black males in PCA GT, which are critical to reduce disparities in PCA-mortality through informing tailored screening, targeted therapy, and cascade testing in families.

Indexed as

Black PeopleGenetic TestingHealthcare DisparitiesProstatic NeoplasmsAfricaBlack or African AmericanDelphi TechniqueHumansMaleUnited StatesDisparitiesGenetic testingHealth equityProstate cancer

Identifiers

PMID39289635
PMCPMC11409532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.